Did vaccination with an infectious bovine rhinotracheitis (IBR) marker vaccine on thirteen cattle farms give rise to chronic wasting among dairy cattle?

At the end of May 1999 the author was asked by the Dutch Animal Health Service (GD) to evaluate problems with 'chronic wasting' cows on 13 farms. The cows were thought to have become ill after vaccination with an IBR marker vaccine. On nine farms a number of cows aborted shortly after vaccination. On eight farms lameness was a problem, as was mastitis. Diarrhoea occurred on four farms. A number of farms had problems with stillbirth, subfertility, abomasal displacement, and decreasing body condition. It was concluded that the abortions, stillbirth, and weak calves at birth in the first weeks after vaccination might be associated with the vaccination. However, the author found no indication that the other problems were associated with the vaccination. This was because the symptoms on the 13 farms were not uniform, and many of the herds already had problems before the herd was vaccinated. The 'chronic wasting' problem cannot be attributed to vaccination with the IBR marker vaccine. 'Chronic wasting' concerns a multifactorial complex of diseases, and has always been present, but has increased in incidence in the last years as a result of 'Holsteinization', a very high milk production, longer periods of housing indoors (and in many cases insufficient quality of the stable and cubicles), a too high work load, and insufficient management.     

Management and herd performance of dairy herds with and without chronic wasting disease

'Chronic wasting' in cattle acquired a special meaning in the Netherlands in 1999. It was used to define animal health problems that were thought to be associated with the use of bovine herpesvirus 1 marker vaccine. Criteria have not been set by which an objectively independent inventory of the problems could be made. The objective of this study was to determine management factors associated with the problem of 'chronic wasting' prior to the use of the BHV1 marker vaccine. Knowledge about these factors could be helpful for generating additional hypotheses about the aetiology of chronic wasting in cattle. A total of 188 farms participated in the study, of which 94 had severe problems with chronic wasting. The other half consisted of control farms matched with the case farms that did not report problems after the use of the BHV1 marker vaccine. Data analyses were performed over the period before (and not at the time of) 'chronic wasting' problems. Data were collected from various sources. A questionnaire was used to collect information on farm management practice. In addition, information on laboratory submissions for 1996 to 1998, animal movements in 1998, roughage analyses of 1997 and 1998, expenses for animal health in 1998, and herd performance in 1995 to 1999 was collected. In the analyses, a distinction was made between information obtained objectively and subjectively. Herds with problems of 'chronic wasting' were larger than herds without wasting problems (animals, surface) but not more intensively managed. 'Wasting' herds had a lower performance in terms of fertility and udder health. In addition, these herds had more contact with other herds through the purchase of animals. There were no differences in farm management practices related to disease control and prevention. Additional studies are required with regard to the patho-physiology of chronic wasting cows. The role of herd size needs more study.     

Possibilities for further research of chronic wasting in dairy cows

In this study, we reviewed the research that has been conducted in relationship with the problem of 'chronic wasting' in dairy cows in the Netherlands as was experienced during 1998 and 1999. Emphasis was drawn towards three aspects of this 'chronic wasting'; the definition, the magnitude, and the possible cause or causes. It appeared that a clear, objective definition of 'chronic wasting' in cows, and of farms with a problem of 'chronic wasting' cows is still lacking. Furthermore, the incidence (of the problem) was restricted to approximately 150 dairy farms at most. Currently, no farms with 'chronic wasting' cows are known. Combined with the uncertainty in the definition, this will hamper future research. Many of the studies were related to the hypothesis that the vaccination with the BHV1 marker vaccine had caused 'chronic wasting' in the cows. None of the results, however, substantiated this hypothesis. Other possible causes have hardly been investigated and further research would be needed to evaluate the role of nutrition, infectious agents, and genetics. However, due to the waning of the phenomenon, the availability of data and controls will be limiting.     

Comparison of performance of dairy herds that were or were not vaccinated with a bovine herpes virus 1 marker vaccine in 1998

This study analysed the effects of the use of bovine herpesvirus 1 (BHV1) marker vaccine on the performance of dairy cattle. In Spring of 1999, vaccination of 12 herds with the BHV1 marker vaccine resulted in severe animal health problems and mortality. The vaccines used on these farms were all from a batch that appeared to be contaminated with bovine virus diarrhoea virus type 2. This led to a general call to farmers and veterinary practitioners to report side-effects of this vaccine. As a result, more than 7000 farmers reported symptoms. The information was obtained by means of a questionnaire; there was no control group. To determine the effects of the use of the marker vaccine, it was necessary to perform a study based on objectively acquired information. The information collected by the Royal Dutch Cattle Syndicate and the office of Identification and Registration was complied into herd indices on production, udder health, reproduction, and culling. Two groups of dairy farms that had used the BHV1 marker vaccine (attenuated and inactivated vaccine) were compared with farms that were certified BHV1-free. The analyses were performed based on intra-herd comparisons, meaning that per herd each index calculated over a certain period of time after the use of the marker vaccine was compared to a similar period of time prior to the use of the marker vaccine. A total of 144 comparisons were made. Seven comparisons were statistically significant. In two comparisons, the results were in favour of the BHV1-free farms and in five comparisons, the result were in favour of the vaccinated farms. Thus use of the BHV1 marker vaccine could not be proven to affect herd performance. The sensitivity of the tests was very high, so with a high level of probability even very small differences in indices between groups would have been detected.     

Outbreak of bovine virus diarrhea on Dutch dairy farms induced by a bovine herpesvirus 1 marker vaccine contaminated with bovine virus diarrhea virus type 2

On 23 February 1999, the Dutch Animal Health Service advised all Dutch veterinary practices to postpone vaccination against bovine herpesvirus 1 (BHV1) immediately. The day before severe disease problems were diagnosed on four dairy farms after vaccination with the same batch of BHV1 marker vaccine. Using monoclonal antibodies, bovine virus diarrhoea virus (BVDV) type 2 was found in the vaccine batch. This paper describes an outbreak of BVDV type 2 infection caused by the use of a batch of modified live BHV1 marker vaccine contaminated with BDVD. Sources of information used were reports of farm visits, minutes of meetings, laboratory results, and oral communications from the people involved. The first symptoms of disease were observed on average six days after vaccination. Morbidity was high on 11 of the 12 farms. On five farms more than 70% of the animals became ill, while on one farm no symptoms could be detected. During the first week after vaccination, feed intake and milk production decreased. During the second week, some animals became clinically diseased having nasal discharge, fever, and diarrhoea. At the end of the second week and at the start of the third week, the number of diseased animals increased rapidly, the symptoms became more severe, and some animals died. Mortality varied among herds. Necropsy most often revealed erosions and ulcers of the mucosa of the digestive tract. In addition, degeneration of the liver, hyperaemia of the abomasum, and swollen mesenterial lymph nodes and swollen spleen were found. On 11 of the 12 farms all animals were culled between 32 and 68 days after vaccination after an agreement was reached with the manufacturer of the vaccine. This was the third outbreak of BVD in cattle after administration of a contaminated vaccine in the Netherlands. The possibilities to prevent contamination of a vaccine as a consequence of infection of fetal calf serum with BVDV are discussed. Improvement of controls to prevent contamination before and during vaccine production, and improvement of the monitoring of side-effects is necessary.     

Practices and opinions of New Zealand beef cattle farmers towards bovine viral diarrhoea control in relation to real and perceived herd serological status

ABSTRACT

Aims: To investigate the seroprevalence of infection with bovine viral diarrhoea (BVD) virus among 75 beef herds and seroconversion in cattle during early pregnancy, and to determine the practices and opinions of farmers towards BVD control and their association with real and perceived herd serological status.

Methods: Blood samples were collected before mating in 75 beef herds across New Zealand from 15 unvaccinated heifers that had delivered their first calf that season. Serum samples were tested for BVD antibodies using ELISA individually, and after pooling samples for each farm. Animals that were antibody-negative were retested at either pregnancy diagnosis or weaning. Farmers were asked to complete a detailed survey about herd demographics, BVD testing and vaccination practices, and opinions towards national BVD control.

Results: Based on the pooled serum antibody ELISA results, there were 28/75 (37%) negative herds, 15/75 (20%) suspect herds, and 32/75 (43%) positive herds. Of 1,117 animals sampled 729 (65.3%) tested negative for BVD virus antibodies; when retested, 47/589 (8.0%) animals from 13/55 (24%) herds had seroconverted. Among 71 famers providing survey responses 11 (15%) believed their herd was infected with BVD, 24 (34%) were unsure and 36 (51%) did not think their herd was infected. Only 19/71 (18%) farmers had performed any BVD testing within the past 5 years and 50/70 (71%) had not vaccinated any cattle for BVD. Support for national BVD eradication programme was strong in 51/71 (56%) respondents, but the biggest challenge to BVD control was considered to be famer compliance. Compared to farmers who did not think their herd was infected, more farmers who thought BVD was present in their herds had previously tested for BVD, would consider testing all replacement calves, and would support establishing a national BVD database; fewer would consider purchasing BVD tested or vaccinated cattle only.

Conclusions and clinical relevance: Only 15% of the beef farmers in this study believed their herds were infected with BVD virus and few of them had undertaken BVD screening. Nevertheless many were supportive of implementing a national BVD control programme. It is likely that the lack of farmer awareness around BVD and the failure of farmers to recognise the potential impacts in their herds are hindering progress in controlling the disease in New Zealand. There are opportunities for New Zealand veterinarians to be more proactive in helping beef farmers explore BVD management options.     

Eradication of infectious bovine rhinotracheitis in Switzerland: review and prospects

Ten years after the first outbreak of infectious bovine rhinotracheitis (IBR) in Swiss dairy cows, the national cattle herd is almost free from infection with IBR virus (bovine herpesvirus 1, BHV 1). The national programme for the eradication of IBR was divided into four phases: (1) Prevention of transmission of the infection by restrictions on trade of bovines and assessment of the prevalence of cattle with antibodies to BHV 1. (2) Slaughtering animals with antibodies to BHV 1 in order to eradicate BHV 1 from breeding herds. (3) Detection and eradication of further BHV 1 reservoirs (e.g. fattening cattle). (4) Monitoring programme and legal actions in order to maintain the favourable situation. Approximately 50,000 animals were slaughtered in the course of the eradication of IBR. The total costs amounted to approximately SFr. 110,000,000 over 10 years. The costs for maintaining the situation are estimated at approximately SFr. 5,000,000 per annum.     

Vaccination of calves with contaminated batches of bovine herpes virus 1 vaccines did not result in infection with bovine virus diarrhea virus

The aim of the experiment was to study whether bovine herpesvirus 1 (BHV1) marker vaccine batches known to be contaminated with bovine virus diarrhoea virus (BVDV) type 1 could cause BVD in cattle. For this purpose, four groups of cattle were used. The first group (n = 4 calves, the positive control group), was vaccinated with vaccine from a batch contaminated with BVDV type 2. The second group (n = 4 calves, the negative control group), was vaccinated with vaccine from a batch that was not contaminated with BVDV. The third group (n = 39 calves), was vaccinated with a vaccine from one of four batches contaminated with BVDV type 1 (seronegative experimental group). The fourth group (n = 6 seropositive heifers), was vaccinated with a vaccine from one of three batches known to be contaminated with BVDV type 1. All cattle were vaccinated with an overdose of the BHV1 marker vaccine. At the start of the experiment, all calves except those from group 4 were seronegative for BVDV and BHV1. The calves from group 4 had antibodies against BVDV, were BVDV-free and seronegative to BHV1. After vaccination, the positive control calves became severely ill, had fever for several days, and BVDV was isolated from nasal swabs and white blood cells. In addition, these calves produced antibodies to BVDV and BHV1. No difference in clinical scores of the other groups was seen, nor were BVDV or BVDV-specific antibody responses detected in these calves; however, they did produce antibodies against BHV1. The remainder of each vaccine vial used was examined for the presence of infectious BVDV in cell culture. From none of the vials was BVDV isolated after three subsequent passages. This indicates that BVDV was either absent from the vials or was present in too low an amount to be isolated. Thus vaccination of calves with vaccines from BHV1 marker vaccine batches contaminated with BVDV type 1 did not result in BVDV infections.     

Maternal immunity to infectious bovine rhinotracheitis and bovine viral diarrhea viruses: duration and effect on vaccination in young calves.

The immune response to modified live-virus bovine viral diarrhea (BVD) vaccine and infectious bovine rhinotracheitis (IBR) vaccine was examined in calves that had received passive maternal antibodies to these viruses. Blood serum samples from vaccinated and control (nonvaccinated) calves were examined for more than 1 year to determine the rate of decline of passive anti-BVD and anti-IBR antibodies and the effect that vaccination had on these antibody titers. The control calves lost their antibodies to BVD and IBR viruses at the rate of one half their remaining antibody titer every 21 days. Calves serologically responded to BVD vaccine at a time when maternal antibody titers remained between 1:96 and 1:20. However, animals did not seroconvert to the IBR vaccine until maternal antibodies had decreased and become undetectable. Evidence is presented to show that although passive immunity will inhibit IBR vaccination, priming for a secondary response will occur so that on subsequent vaccination, at a time when maternal antibodies have disappeared, the animals will respond anamnestically to IBR vaccination.     

Bovine viral diarrhoea virus seroprevalence and vaccination usage in dairy and beef herds in the Republic of Ireland

Background

Bovine viral diarrhoea (BVD) is an infectious disease of cattle with a worldwide distribution. Herd-level prevalence varies among European Union (EU) member states, and prevalence information facilitates decision-making and monitoring of progress in control and eradication programmes. The primary objective of the present study was to address significant knowledge gaps regarding herd BVD seroprevalence (based on pooled sera) and control on Irish farms, including vaccine usage.

Methods

Preliminary validation of an indirect BVD antibody ELISA test (Svanova, Biotech AB, Uppsala, Sweden) using pooled sera was a novel and important aspect of the present study. Serum pools were constructed from serum samples of known seropositivity and pools were analysed using the same test in laboratory replicates. The output from this indirect ELISA was expressed as a percentage positivity (PP) value. Results were used to guide selection of a proposed cut-off (PCO) PP. This indirect ELISA was applied to randomly constructed within-herd serum pools, in a cross-sectional study of a stratified random sample of 1,171 Irish dairy and beef cow herds in 2009, for which vaccination status was determined by telephone survey. The herd-level prevalence of BVD in Ireland (percentage positive herds) was estimated in non-vaccinating herds, where herds were classified positive when herd pool result exceeded PCO PP. Vaccinated herds were excluded because of the potential impact of vaccination on herd classification status. Comparison of herd-level classification was conducted in a subset of 111 non-vaccinating dairy herds using the same ELISA on bulk milk tank (BMT) samples. Associations between possible risk factors (herd size (quartiles)) and herd-level prevalence were determined using chi-squared analysis.

Results

Receiver Operating Characteristics Analysis of replicate results in the preliminary validation study yielded an optimal cut-off PP (Proposed Cut-off percentage positivity - PCO PP) of 7.58%. This PCO PP gave a relative sensitivity (Se) and specificity (Sp) of 98.57% and 100% respectively, relative to the use of the ELISA on individual sera, and was chosen as the optimal cut-off since it resulted in maximization of the prevalence independent Youden’s Index.The herd-level BVD prevalence in non-vaccinating herds was 98.7% (95% CI - 98.3-99.5%) in the cross-sectional study with no significant difference between dairy and beef herds (98.3% vs 98.8%, respectively, p = 0.595).An agreement of 95.4% was found on Kappa analysis of herd serological classification when bulk milk and serum pool results were compared in non-vaccinating herds. 19.2 percent of farmers used BVDV vaccine; 81% of vaccinated herds were dairy. A significant association was found between seroprevalence (quartiles) and herd size (quartiles) (p < 0.01), though no association was found between herd size (quartiles) and herd-level classification based on PCO (p = 0.548).

Conclusions

The results from this study indicate that the true herd-level seroprevalence to Bovine Virus Diarrhoea (BVD) virus in Ireland is approaching 100%. The results of the present study will assist with national policy development, particularly with respect to the national BVD eradication programme which commenced recently.     

Evaluation of Mycoplasma hyopneumoniae inactivated vaccine in pigs under field conditions

An inactivated vaccine prepared from broth culture supernatant of Mycoplasma hyopneumoniae with an aluminum adjuvant was evaluated in three herds (herd A: specific pathogen-free herd, herd B: high health status herd with no clinical signs of respiratory infection, herd C: low health status herd with serious epidemiological and economical problems). A total of 212 pigs from the three herds were divided into two groups. One group was injected twice with the vaccine at 4-week intervals and the other was a control group. No adverse reactions were noted following the vaccinations either systematically or locally in any of the vaccinated pigs from any of the herds. In herd A, the vaccination provided antibody response within 4 weeks after the second vaccination and antibody responses continued for more than 12 weeks. In herds B and C, the number of pigs with lung lesions, mean percentage of lung lesions, and the numbers of M. hyopneumoniae recovered from pigs at slaughter in the vaccinated group were significantly (P < 0.05) reduced compared to the control group. Furthermore, vaccination resulted in improved average daily weight gain (ADG), improved feed conversion ratio (FCR), and improved days to market weight in herd C, whereas no difference in growth performance was shown in herd B. It is suggested that the inactivated vaccine prepared from broth culture supernatant of M. hyopneumoniae is effective in reducing clinical signs and lung lesions. Also, vaccination resulted in improved growth performance in herds where clinical signs and economic losses were significant.     

Prevalence of chronic wasting in Dutch dairy herds with a history of chronic health problems

The prevalence of chronic wasting in cattle in March and April 2000 was studied on 218 dairy farms with a history of health problems accompanied by wasting, following reports in the media suggesting that chronic wasting was a substantial problem on Dutch dairy farms. A telephone call revealed that the health problems had resolved on 41 farms; 16 of these farms had culled all cattle. Two farmers refused co-operation. On the remaining 175 farms the animals were inspected and was completed a questionnaire. A high percentage of culling for of health reasons (on average 18.1% of young stock and adult cattle) and an increased mortality rate (4.8%) were reported on the farms visited. In only two of the 175 inspected herds, more than 20 percent of cattle were found showing signs of wasting. These two herds were identified as 'chronic wasting herds'. The prevalence of such herds was low in this study. Consequently, it is likely that there were very few 'chronic wasting herds' among the whole Dutch dairy population in March/April 2000.     

A Controlled Field Study Using Live Virus Vaccines and an Antiserum in a Preconditioning Program

Thirty-five vaccinates and 29 control beef calves from five farms were studied. Vaccinates in group 1 received a modified live virus vaccine against infectious bovine rhinotracheitis (IBR) and bovine virus diarrhea (BVD) 30 days after shipment; vaccinates in groups 2, 3 and 4 received live virus vaccines agains IBR and bovine parainfluenza 3 (PI3) seven to 17 days before shipment. Half of group 5 were given bovine origin antiserum containing antibodies against IBR, BVD and PI3. Three weeks later, the animals that had received serum were given a live modified vaccine containing IBR, BVD and PI3. In group 1, WBC counts were lower in the vaccinates than in the controls for two weeks after vaccination. WBC counts in groups 3 and 4 were higher in vaccinates than in controls after addition to the feedlot. Seroconversions to BVD virus occured in all groups. Clinical disease apparently due to BVD affected one vaccinated calf in group 2 and eight calves in group 5. Combined weight gains were significantly higher in three groups of calves vaccinated before shipment compared to unvaccinated control animals after addition to the feedlot. Vaccination with IBR and PI3 live virus vaccines should be given at least 17 days before shipment to feedlots containing infected cattle. Antiserum containing antibodies against the three viruses showed no apparent advantage in preventing clinical respiratory disease over control calves not receiving the serum.     

Evidence for an immunocompromising effect of bovine pestivirus on bovid herpesvirus 1 vaccination

Five calves were given live intranasal vaccine against bovid herpesvirus 1 (BHV1) two days after intranasal inoculation of bovine pestivirus (BVDV). Another 5 were vaccinated in the absence of BVDV. Control unvaccinated groups were also maintained. All calves were challenged with virulent BHV1. The unvaccinated calves developed signs of infectious bovine rhinotracheitis (IBR) and both vaccinated groups showed a similar degree of clinical protection from IBR. Those given BVDV before vaccination shed up to 140 times more BHV1 (P less than 0.01) in the nasal mucus following challenge than those which had received BHV1 vaccine alone. The epidemiological significance of this is discussed.     

Use of a benefit function to assess the relative investment potential of alternative farm animal disease prevention strategies

Using the example of bovine viral diarrhoea (BVD) in Scottish suckler (cow-calf) beef herds, this paper demonstrated a method to establish the maximum average net benefit of disease control under specific epidemiological and farm business circumstances. Data were generated for the method using a stochastic epidemiological model set to estimate the mean and variance of control costs and output losses from BVD for 50-cow or 120-cow herds, either free of BVD at the outset or of unknown BVD status. Control of disease was by increased investment in a variety of (‘biosecurity’) measures aimed at reducing the probability of virus entering the closed herd in any 1 year of a 10-year period of simulated exposure to risk from BVD virus introduction either with or without vaccination. Herds free of BVD at the outset enjoyed much greater maximum average net benefits than herds of unknown BVD status. Best allocations of hypothetical incentives to encourage farmers to establish their freedom from BVD were therefore outlined. Vaccination and biosecurity were generally found to be complementary rather than substitutes for one another. The advantages of the maximum net benefit measure over the more usual average total cost of endemic disease were demonstrated and discussed. The maximum net benefit method focuses on the relationship between costs and benefits, which often exhibits diminishing marginal returns meaning that profit maximisation and disease minimisation are incompatible. The method can also allow for constraints on and competition for limited farm resources. It was argued that these attributes are important to persuade farmers to invest in animal health.     

Identification of an introduced bovine herpesvirus type 1 strain in a closed dairy herd by experimental virus reactivation followed by DNA restriction enzyme analysis

In a closed dairy herd in the province of Utrecht in 1995, nine replacement heifers were erroneously intramuscularly vaccinated with Tracherine, a live virus IBR vaccine. More than 18 months later, serology of the herd revealed that a large part of the herd had developed an antibody response towards BHV1 (62 of 87 animals). To investigate whether Tracherine had recirculated on the farm, four BHV1 antibody positive animals, of which two had been vaccinated with Tracherine, were treated with corticosteroids to reactivate latent BHV1. Two virus isolates were obtained and subsequently analysed by resctriction enzyme analysis. Both isolates were identified as BHV1.1 subtypes. One of the isolates was clearly distinct from Tracherine and was most likely a BHV1 field virus. A BHV1 field virus was most likely introduced into the farm even though the herd was closed, the animals had not been in contact with other cattle, and preventive hygienic measures had been implemented. There was no indication that Tracherine had recirculated.     

Evidence for an immunocompromising effect of bovine pestivirus on bovid herpesvirus 1 vaccination

Five calves were given live intranasal vaccine against bovid herpesvirus 1 (BHV1) two days after intranasal inoculation of bovine pestivirus (BVDV). Another 5 were vaccinated in the absence of BVDV. Control unvaccinated groups were also maintained. All calves were challenged with virulent BHV1. The unvaccinated calves developed signs of infectious bovine rhinotracheitis (IBR) and both vaccinated groups showed a similar degree of clinical protection from IBR. Those given BVDV before vaccination shed up to 140 times more BHV1 (P<0.01) in the nasal mucus following challenge than those which had received BHV1 vaccine alone. The epidemiological significance of this is discussed.     

Factors associated with being a bovine-virus diarrhoea (BVD) seropositive dairy herd in the M[oslash]re and Romsdal County of Norway

Factors associated with being a bovine-virus diarrhoea (BVD) seropositive dairy herd were studied in a case-control study of 314 dairy herds in the M[oslash]re and Romsdal County of Norway. Information was collected through a mailed questionnaire, and associations were modeled using conditional logistic regression after selecting variables by a best-subset procedure. Purchasing of animals, use of common pasture, herd-to-herd contact over pasture fences, purchasing cattle with insufficient health (about BVD) documentation, and not using dairy advisors were associated with higher risk. In addition, younger farmers were more likely to have a bovine-virus diarrhoea seropositive herd than older farmers. ‘Other animal traffic', including use of common animal housing in the summer months and exchange of calves between farmers were also risk factors. Collectively, these factors could explain 51% of the seropositive herds.     

Disease screening profiles and colostrum management practices on 16 Irish suckler beef farms

Background

Calf output is a key element in determining the profitability of a suckler beef enterprise. Infectious agents such as Bovine Virus Diarrhoea (BVD) virus, colostrum management and parasitic challenge can all affect calf output. Prior to the national BVD eradication programme, there was little published information on either the prevalence or effect of BVD in Irish beef herds. There is little published information on colostrum management practices in Irish commercial beef herds and there have also been few studies published on the prevalence of liver fluke or rumen fluke infection in Irish beef herds. Sixteen farms participating in the Teagasc/Farmers Journal BETTER farm beef programme were used in this study. Fourteen herds were screened for the presence of BVD virus in 2010 using RT-PCR. In 13 herds, blood samples were collected from calves (2–14 days of age) in November 2011 - April 2012 to determine their passive immune status using the zinc sulphate turbidity (ZST) test, while in 12 herds, blood and faecal samples were taken in order to determine the level of exposure to gastrointestinal and hepatic helminths.

Results

The overall prevalence of BVD virus-positive cattle was 0.98% (range 0 - 3% per herd, range 0.6 - 3.0% per positive herd). Eighteen of the 82 calves (22%) sampled had ZST values less than 20 units (herd mean range 17.0 – 38.5 units) indicating a failure of passive transfer. The overall animal-level (herd-level) prevalence of liver fluke and rumen fluke infection in these herds was 40.5% (100%) and 20.8% (75%), respectively.

Conclusions

The potential costs associated with the presence of animals persistently infected with BVD virus through the increased use of antibiotics; the rate of failure of passive transfer of colostral immunoglobulins and the high prevalence of liver fluke infection in these herds highlight that some Irish suckler beef farms may not be realizing their economic potential due to a range of herd health issues. The use of farm-specific herd health plans should be further encouraged on Irish suckler beef farms.